Goldman Sachs Lowers Molina Healthcare Price Target to $124, Maintains Neutral Rating

Goldman Sachs has adjusted its price target for Molina Healthcare (MOH) downwards, setting it at $124 from a previous $167. The investment bank, however, reiterated its "Neutral" rating on the healthcare provider's stock. This move by Goldman Sachs aligns with a broader trend observed across the financial sector. Several other prominent institutions, including Deutsche Bank, Barclays, UBS, Cantor Fitzgerald, Jefferies, and TD Cowen, have also recently reduced their price targets for Molina Healthcare. This collective adjustment by multiple analysts suggests a less optimistic outlook for MOH shares, potentially signaling downward pressure on the stock in the near term.